Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery

Inclusion Criteria: * Signed informed consent * Males and females aged ≥18 years * Patients treated with ticagrelor * Emergency Coronary Artery Bypass Graft (CABG) surgery * Cardiothoracic surgery requiring CPB ≤24 hours following the last dose of ticagrelor Exclusion Criteria: * Any cardiothoracic surgery \>24 hours after last dose of ticagrelor * Resuscitation * Any pre-operative coagulopathy unrelated to ticagrelor or standard of care (SoC) to undergo surgery with CPB * Sepsis (according to Sepsis 3.0 definition) * Malignant tumor * Left ventricular ejection fraction (LVEF) \< 20% * History or presence of significant pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, neurologic, or psychiatric disease which, in the opinion of the Investigator, increases risk to the patient or could confound the results of the study * Presence of end-stage renal disease or currently receiving renal replacement therapy * Patients with a history of major organ transplantation * Patients in acute sickle cell crisis * Patients concurrently requiring immunosuppressive therapy, with the exception of corticosteroids, or who are profoundly immune suppressed (e.g. CD4 \< 200 or neutropenia with ANC \< 1000/μL) * Women of childbearing potential with a positive pregnancy test performed during the current admission or who are lactating. Women are considered not of child bearing potential if they have been sterilized at least 6 months prior to the study or if they are post-menopausal, defined as amenorrhea for at least 12 months